ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Researchers at the University of California, San Francisco, have figured out how a mutation in a protein, the TERT promoter, can grant tumor cells the ability to multiply with abandon. In a paper in Cancer Cell (2018, DOI: 10.1016/j.ccell.2018.08.003), UCSF’s Joseph F. Costello identifies the GABP-β1L subunit of the protein as a potentially important new cancer drug target. Telo Therapeutics, a start-up founded by Costello and his former graduate student Robert Bell, is working with GlaxoSmithKline to screen small-molecule libraries for inhibitors of the subunit.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X